Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 20.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,311,700 shares of the company's stock after purchasing an additional 221,908 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.52% of Maravai LifeSciences worth $7,149,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MRVI. Massachusetts Financial Services Co. MA grew its holdings in shares of Maravai LifeSciences by 29.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock worth $25,420,000 after buying an additional 1,062,485 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Maravai LifeSciences by 4.9% during the fourth quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company's stock worth $23,166,000 after purchasing an additional 200,411 shares during the last quarter. Jennison Associates LLC lifted its holdings in shares of Maravai LifeSciences by 0.3% during the fourth quarter. Jennison Associates LLC now owns 2,990,414 shares of the company's stock worth $16,298,000 after purchasing an additional 9,769 shares during the period. Geode Capital Management LLC grew its position in Maravai LifeSciences by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,794,961 shares of the company's stock valued at $15,236,000 after buying an additional 42,884 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Maravai LifeSciences by 17,912.9% in the 4th quarter. Marshall Wace LLP now owns 2,778,497 shares of the company's stock valued at $15,143,000 after buying an additional 2,763,072 shares during the period. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Trading Down 3.9%

NASDAQ:MRVI traded down $0.08 on Wednesday, reaching $1.98. The stock had a trading volume of 2,039,035 shares, compared to its average volume of 2,338,520. The company has a market cap of $503.59 million, a price-to-earnings ratio of -1.21 and a beta of 0.19. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.67 and a 12-month high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The firm's fifty day moving average is $2.14 and its two-hundred day moving average is $4.14.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $46.85 million during the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. Maravai LifeSciences's revenue was down 26.9% compared to the same quarter last year. Equities analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MRVI. UBS Group lowered their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Baird R W downgraded shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Robert W. Baird lowered their price target on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday. Bank of America reduced their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Finally, Craig Hallum lowered their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $6.64.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.